Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab
type: MedicalStudy
description: Indentifying Epigenetic Biomarkers From Peripheral Blood of Advanced Osteosarcoma Patients, Who Recieve Famitinib and Camrelizumab Based on hMe-Seal Technique
status: UNKNOWN
study design: OBSERVATIONAL
start date: 2019-12-01
end date: 2021-12-31
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT03919539
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Peking University People's Hospital
study subject: Drug Resistance to Famitinib and Camrelizumab
study subject: Biomarkers for Efficacy and Toxicity
keywords: OBSERVATIONAL
keywords: UNKNOWN
keywords: Drug Resistance to Famitinib and Camrelizumab
keywords: Biomarkers for Efficacy and Toxicity

AI Analytics
type: Organization